Monograph Details
|
|
Eye Disorders
> Ocular allergy/inflammation
|
|
NEVANAC |
| Manufacturer |
|
Alcon Laboratories, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
NSAID. |
| Generic Name |
|
Nepafenac 0.1%, oph. susp; contains benzalkonium chloride. |
| Indications |
|
Post-operative pain and inflammation following cataract surgery. |
| Children |
|
<10yrs: not recommended. |
| Adults |
|
≥10yrs: 1 drop in affected eye(s) 3 times daily starting one day before surgery, continued on day of surgery, and through first 2 weeks post-op. |
| Precautions |
|
Bleeding tendencies. May delay wound healing. Complicated/repeat ocular surgeries. Corneal defects/denervation. Ocular surface diseases. Rheumatoid arthritis. Diabetes. Monitor cornea; discontinue if corneal epithelial breakdown occurs. Contact lenses (remove during therapy). Risk of corneal adverse events may be increased if used more than 24 hours before surgery, or beyond 14 days post-op. Pregnancy (Cat.C; avoid during 3rd trimester). Nursing mothers. |
| Interactions |
|
May potentiate oral anticoagulants, others that prolong bleeding. |
| Adverse Reactions |
|
Ocular effects (eg, capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, sticky sensation, edema, dry eye, lid margin crusting, discomfort, hyperemia, pain, pruritus, photophobia, tearing, vitreous detachment), headache, hypertension, GI upset, sinusitis. |
| How Supplied |
|
Susp—3mL |
|
|
|
|
